CD276 and cancer: The expression rate of B7-H3 exhibits significant variability among cancer subtypes and study cohorts, ranging from 73.4% in ductal carcinoma in situ (DCIS) tumors to 90.6% in cohorts predominantly comprising invasive ductal and lobular carcinomas [132].